Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Inclusion criteria

• Men and women between the ages of 18 and 65 at the time of surgery
• SG or RYBP as bariatric procedure.
• With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI>40.0 kg/m2 at the time of surgery.
• Provision of an informed consent form signed and personally dated by the patient.
• With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).

Exclusion criteria

• Any previous gastrointestinal surgery
• Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS
• End stage kidney disease (eGFR <15 ml/min/1.73m2) or liver cirrhosis at baseline
• Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)
• Known type 1 diabetes or LADA diabetes
• Women who become pregnant during the follow-up period
• Current drug or alcohol abuse
• Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.